Advertisement

Medical Treatment of Hemangiomas

  • Jochen Rössler
  • Charlotte Marie Niemeyer

Abstract

Cytotoxic drugs are a valuable option for the treatment of hemangiomas that interfere with normal functions (vision, breathing, eating, voiding or stooling), result in serious disfigurement, or give rise to ulceration, bleeding, infection, pain, heart and liver failure. Corticosteroids administered systemically are considered first line medical therapy for proliferating hemangiomas. If resistance to corticosteroid treatment is observed or when visceral involvement is present, other cytotoxic drugs such as vincristine or cyclophosphamide can be used. Interferon is effective and was prescribed until recently. However, because of severe neurological toxicity it is increasingly omitted. Here, we summarize the mode of action and side effects as well as the current experience with these drugs used systemically or intra-lesionally.

Keywords

Obstructive Sleep Apnea Corticosteroid Therapy Interferon Alpha Infantile Hemangioma Hemorrhagic Cystitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Frieden IJ, Haggstrom AN, Drolet BA et al (2005) Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7–9, Bethesda, Maryland, USA. Pediatr Dermatol 22:383–406CrossRefPubMedGoogle Scholar
  2. 2.
    Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ (2001) Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 137:1208–1213PubMedGoogle Scholar
  3. 3.
    Enjolras O, Breviere GM, Roger G et al (2004) [Vincristine treatment for function-and life-threatening infantile hemangioma]. Arch Pediatr 11:99–107CrossRefPubMedGoogle Scholar
  4. 4.
    Hurvitz SA, Hurvitz CH, Sloninsky L, Sanford MC (2000) Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol 22:527–532CrossRefPubMedGoogle Scholar
  5. 5.
    Dubois J, Hershon L, Carmant L et al (1999) Toxicity profile of interferon alfa-2b in children: A prospective evaluation. J Pediatr 135:782–785CrossRefPubMedGoogle Scholar
  6. 6.
    Boon LM, MacDonald DM, Mulliken JB (1999) Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 104:1616–1623CrossRefPubMedGoogle Scholar
  7. 7.
    Zarem HA, Edgerton MT (1967) Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg 39:76–83CrossRefPubMedGoogle Scholar
  8. 8.
    Hasan Q, Tan ST, Xu B, Davis PF (2003) Effects of five commonly used glucocorticoids on haemangioma in vitro. Clin Exp Pharmacol Physiol 30:140–144CrossRefPubMedGoogle Scholar
  9. 9.
    Blei F, Wilson EL, Mignatti P, Rifkin DB (1993) Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 155:568–578CrossRefPubMedGoogle Scholar
  10. 10.
    Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ (2001) Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 137:1208–1213PubMedGoogle Scholar
  11. 11.
    Sadan N, Wolach B (1996) Treatment of hemangiomas of infants with high doses of prednisone. J Pediatr 128:141–146CrossRefPubMedGoogle Scholar
  12. 12.
    Rossler J, Wehl G, Niemeyer CM (2007) Evaluating systemic prednisone therapy for proliferating haemangioma in infancy. Eur J Pediatr (Epub ahead of print)Google Scholar
  13. 13.
    Pope E, Krafchik BR, Macarthur C et al (2007) Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics 119:e1239–e1247CrossRefPubMedGoogle Scholar
  14. 14.
    Christison-Lagay ER, Burrows PE, Alomari A et al (2007) Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg 42:62–67CrossRefPubMedGoogle Scholar
  15. 15.
    Sloan GM, Reinisch JF, Nichter LS et al (1989) Intralesional corticosteroid therapy for infantile hemangiomas. Plast Reconstr Surg 83:459–467CrossRefPubMedGoogle Scholar
  16. 16.
    Garzon MC, Lucky AW, Hawrot A, Frieden IJ (2005) Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 52:281–286CrossRefPubMedGoogle Scholar
  17. 17.
    Fawcett SL, Grant I, Hall PN et al (2004) Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 57:168–171CrossRefPubMedGoogle Scholar
  18. 18.
    Gidding CE, Kellie SJ, Kamps WA, de Graaf SS (1999) Vincristine revisited. Crit Rev Oncol Hematol 29:267–287CrossRefPubMedGoogle Scholar
  19. 19.
    Herrero HA, Escobosa SO, Acha GT (2007) Successful treatment with vincristine in PHACES syndrome. Clin Transl Oncol 9:262–263CrossRefGoogle Scholar
  20. 20.
    Enjolras O, Wassef M, Mazoyer E et al (1997) Infants with Kasabach-Merritt syndrome do not have “true” hemangiomas. J Pediatr 130:631–64CrossRefPubMedGoogle Scholar
  21. 21.
    Sarkar M, Mulliken JB, Kozakewich HP et al (1997) Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 100:1377–1386CrossRefPubMedGoogle Scholar
  22. 22.
    Haisley-Royster C, Enjolras O, Frieden IJ, et al (2002) Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 24:459–462CrossRefPubMedGoogle Scholar
  23. 23.
    Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326:1456–1463CrossRefPubMedGoogle Scholar
  24. 24.
    Sidky YA, Borden EC (1987) Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyteinduced vascular responses. Cancer Res 47:5155–5161PubMedGoogle Scholar
  25. 25.
    Barlow CF, Priebe CJ, Mulliken JB et al (1998) Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 132:527–530CrossRefPubMedGoogle Scholar
  26. 26.
    Worle H, Maass E, Kohler B, Treuner J (1999) Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication. Eur J Pediatr 158:344CrossRefPubMedGoogle Scholar
  27. 27.
    Kaselas C, Tsikopoulos G, Papouis G, Kaselas V (2007) Intralesional administration of interferon A for the management of severe haemangiomas. Pediatr Surg Int 23:215–218CrossRefPubMedGoogle Scholar
  28. 28.
    Pienaar C, Graham R, Geldenhuys S, Hudson DA (2006) Intralesional bleomycin for the treatment of hemangiomas. Plast Reconstr Surg 117:221–226CrossRefPubMedGoogle Scholar
  29. 29.
    Perry BN, Govindarajan B, Bhandarkar SS et al (2006) Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 126:2316–2322CrossRefPubMedGoogle Scholar
  30. 30.
    Berard M, Sordello S, Ortega N et al (1997) Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas. Am J Pathol 150:1315–1326PubMedGoogle Scholar
  31. 31.
    Takahashi K, Mulliken JB, Kozakewich HP (1994) Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93:2357–2364CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Jochen Rössler
    • 1
  • Charlotte Marie Niemeyer
    • 2
  1. 1.Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent MedicineUniversity Hospital of FreiburgFreiburgGermany
  2. 2.Clinic IV of Pediatric Hematology and Oncology, Centre for PediatricsUniversity of FreiburgFreiburgGermany

Personalised recommendations